PLCG2 and colorectal carcinoma: To investigate whether PLCG2 was associated with chemotherapy sensitivity in CRC patients, we predicted the IC50 of drugs in two different PLCG2 expression groups and discovered that CRC patients with low PLCG2 expression might be more sensitive to gemcitabine, and those with high PLCG2 expression might be more sensitive to cisplatin, docetaxel, etoposide and methotrexate (Figure S9G).